3.4.24.86: ADAM 17 endopeptidase
This is an abbreviated version!
For detailed information about ADAM 17 endopeptidase, go to the full flat file.
Word Map on EC 3.4.24.86
-
3.4.24.86
-
adam10
-
ectodomains
-
sheddase
-
metalloproteinases
-
endothelial
-
phorbol
-
sirna
-
amyloid
-
egf
-
alzheimer
-
notch
-
angiotensin
-
membrane-anchored
-
arthritis
-
amphiregulin
-
ace2
-
hb-egf
-
hydroxamate
-
timp-3
-
heparin-binding
-
l-selectin
-
trans-signaling
-
angiotensin-converting
-
covid-19
-
alpha-secretase
-
mmp-2
-
sars-cov-2
-
egf-like
-
juxtamembrane
-
medicine
-
prodomains
-
furin
-
secretase
-
tgf-alpha
-
membrane-proximal
-
tmprss2
-
sil-6r
-
non-amyloidogenic
-
cxcl16
-
rhomboid
-
epiregulin
-
gamma-secretase
-
neuregulins
-
molecular biology
-
adamalysins
-
metzincins
-
membrane-tethered
-
fractalkine
-
betacellulin
-
marimastat
-
analysis
-
egfr-dependent
- 3.4.24.86
- adam10
- ectodomains
- sheddase
- metalloproteinases
- endothelial
-
phorbol
- sirna
-
amyloid
- egf
- alzheimer
- notch
- angiotensin
-
membrane-anchored
- arthritis
- amphiregulin
- ace2
- hb-egf
- hydroxamate
- timp-3
-
heparin-binding
- l-selectin
-
trans-signaling
-
angiotensin-converting
- covid-19
- alpha-secretase
- mmp-2
- sars-cov-2
-
egf-like
-
juxtamembrane
- medicine
- prodomains
- furin
-
secretase
- tgf-alpha
-
membrane-proximal
- tmprss2
-
sil-6r
-
non-amyloidogenic
- cxcl16
- rhomboid
- epiregulin
- gamma-secretase
- neuregulins
- molecular biology
- adamalysins
-
metzincins
-
membrane-tethered
- fractalkine
- betacellulin
- marimastat
- analysis
-
egfr-dependent
Reaction
Narrow endopeptidase specificity. Cleaves Pro-Leu-Ala-Gln-Ala-/-Val-Arg-Ser-Ser-Ser in the membrane-bound, 26-kDa form of tumor necrosis factor alpha (TNFalpha). Similarly cleaves other membrane-anchored, cell-surface proteins to "shed" the extracellular domains =
Synonyms
(TACE/ADAM17/CD156q), (TACE:ADAM17), a disintegrin and metallo protease domain 17, a disintegrin and metalloprotease 17, a disintegrin and metalloprotease-17, a disintegrin and metalloproteinase 17, a disintegrin and metalloproteinase-17, ADAM-17, ADAM17, ADAM17 proteinase, ADAM17/tumor necrosis factor-alpha (TNF-A)converting enzyme, ADAMTS-2, CD156, H-TACE, human TACE B, metalloprotease TACE, metalloprotease-disintegrin tumour necrosis factor alpha convertase, metalloproteinase ADAM17, pro tumor necrosis factor cleavage enzyme, pro-tumor necrosis factor-alpha-processing enzyme, proteinase, pro-tumor necrosis factor (9CI), sheddase, TACE, TACE proteinase, TACE/ADAM17, TNF converting enzyme, TNF-alpha convertase, TNF-alpha converting enzyme, TNF-alpha processing protease, TNFalpha converting enzyme, tumor necrosis factor alpha convertase, tumor necrosis factor alpha converting enzyme, tumor necrosis factor alpha-converting enzyme, tumor necrosis factor-alpha converting enzyme, tumor necrosis factor-alpha-converting enzyme, tumour necrosis factor alpha-converting enzyme, tumour necrosis factor-alpha converting enzyme
ECTree
3.4.24.86 ADAM 17 endopeptidaseAdvanced search results
results (
results (Application
Application on EC 3.4.24.86 - ADAM 17 endopeptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
analysis
development of a fluorescence resonance energy transfer-based biosensor that quantitatively reports the kinetics of TACE activity in live cells
medicine
molecular biology
medicine
-
over-expression of TNF-alpha has been implicated in diseases such as rheumatoid arthritis, Crohn's disease, septic shock, AIDS, insulin resistance, cachexia and cancer
medicine
-
TACE inhibitors prevent TNFalpha release and protect against TNFalpha-mediated disease
medicine
-
tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor, activating TACE by pharmacological manipulation might prove beneficial in Alzheimer's disease
medicine
-
targeting this key enzyme for therapeutic intervention in inflammatory diseases, cancer and AIDS
medicine
-
TACE plays a role in the pathogenesis of endometriosis, a benign gynecologic disorder
medicine
-
TACE as target for drug discovery, potential therapeutic target in the areas of arthritis, cancer, diabetes and HIV cachexia
medicine
-
pharmaceutical industry is attempting to design specific TACE inhibitors to treat inflammatory diseases, may also be beneficial in treating certain cancers
medicine
-
isolation of TACE facilitates the development of therapeutically useful inhibitors of TNF-alpha release
medicine
-
putative cellular targets of a therapeutic strategy in neurodegenerative prion diseases
medicine
-
TNF-alpha thought to be a selective anti-tumor agent and a contributor to cachexia in cancer patients, clinical trials for cancer
medicine
-
therapeutic potential of TACE inhibitors benefit in treating autoimmune diseases like Crohn's disease or rheumatoid arthritis
medicine
-
TACE has implications in the pathogenesis of myocarditis and may have influence on advanced cardiac dysfunction in myocarditis
medicine
-
ADAM-17 is a putative target for treatment of neuroinflammatory diseases
medicine
-
ADAM-17 is a putative target for treatment of neuroinflammatory diseases
medicine
-
ADAM17/TACE might be an important therapeutic target. The blocking of ADAM17/TACE expression and/or the evaluation and development of specific TACE inhibitors might have therapeutic potential even in later stages of cancer. Furthermore, ADAM17/TACE might be useful as a diagnostic marker of pancreatic cancer to distinguish between PDAC and chronic pancreatitis. Aberrant ADAM17/TACE expression might be a diagnostic and therapeutic target in human pancreatic ductal adenocarcinoma
medicine
-
inhibition of TACE might be a potential therapeutic strategy for neuroprotection after focal ischemic stroke
medicine
-
TACE proteolysis is a promoter of stroke-induced SVZ progenitor cell neurogenesis, and suggest this protease activity may represent an attractive therapeutic target for stroke recovery
medicine
-
in order to explore the role of TACE and NF-kappa B in hyperoxia-induced brain-ischemic tolerance, rodents are exposed to 95% inspired hyperoxia 4 h/day for six consecutive days or for 24 continous hours (prolonged hyperoxia). 24 h after the treatment. TACE, serum TNF-alpha and phosphor-kappaBalpha expression is up-regulated. Brain ischemic tolerance, inspired hyperoxia and prolonged hyperoxia may partly exert their effects via triggering TACE/TNF-alpha /NF-kappaB
medicine
-
in this study the relationship between long-term alcohol consumption and the concentration of TACE in peripheral blood mononuclear cells and its substrate- soluble TNF-alpha receptor type 1 in plasma in psoriasis patients is analysed. The study is conducted among 44 patients (aged 30-59 years) with early-onset, plaque-type psoriasis. 38 patients (aged 29-61 years) with other than psoriasis chronic dermatologic disorders are controls. The data on alcohol consumption during previous 10 years are obtained with a structured questionnaire. The severity of the disease is assessed using Psoriasis Area and Severity Index (PASI), and concentrations of TACE in peripheral blood mononuclear cells lysate and soluble TNF-alpha receptor type 1 in plasma is assessed with a quantitative sandwich enzyme immunoassay technique. The alcohol abuse contributes to the increase of TACE expression in blood mononuclear cells and also to the elevated plasma soluble TNF-alpha receptor type 1 concentration in psoriasis patients
medicine
-
the data presented herein show TACE expression in endocrine cancers and further support a role for TACE in breast cancer apoptosis
medicine
-
the increased gingival crevicular fluid TACE levels in persons with periodontitis and their positive correlation with receptor activator of NF-kappaB ligand indicate an association of this enzyme with alveolar bone loss
medicine
-
the relationship between ADAM17 and TNF polymorphisms, circulating levels of shed ADAM17 substrates, and cardiovascular risk in a prospective cohort of coronary artery disease patients is investigated. Five tag single-nucleotide polymorphisms (SNPs) of the ADAM17 gene as well as four previously described TNF SNPs are genotyped in the Atherogene Study composed of 1400 coronary artery disease patients among which 136 died from a cardiovascular cause. Soluble TNF, soluble TNF receptor 1, and soluble TNF receptor 2 concentrations are all significantly elevated in patients with future cardiovascular death, independently of other clinical/biological variables. The ADAM17-154A allele is found associated with a 14% increase of soluble TNF levels as compared to the -154C allele. Individuals carrying the 747Leu allele display a borderline increased risk of future cardiovascular death
medicine
-
1,25-dihydroxyvitamin D inhibition of TACE is a potential common mechanism underlying the efficacy of therapy with 1,25-dihydroxyvitamin D or its analogs to improve outcomes in chronic kidney disease. 1,25-dihydroxyvitamin D prevents/moderates not only the onset and progression of parathyroid TACE/TGFalpha-driven secondary hyperparathyroidism, but renal TACE/TGFalpha-driven fibrotic and inflammatory lesions to the renal parenchyma, and TACE/TNFalpha-driven systemic inflammation
medicine
-
anti-Ro/SSA autoantibodies determine TACE pro-domain shedding suggesting that TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA autoantibody-stimulated cells. Adalimumab appears to be significantly more efficacious than Etanercept in preventing TACE activation caused by anti-Ro/SSA autoantibodies. Regulation of TACE may participate in the pathogenic role of autoantibodies and the modulation of TACE expression by TNF-alpha antagonists might contribute to the beneficial effect of these drugs in inflammatory and autoimmune diseases
medicine
-
during acute H pylori infection, CagL dissociates ADAM17 from the integrin alpha(5)beta1 and activates ADAM17-dependent, nuclear factor-kappaB-mediated repression of HKalpha, i.e. gastric H, K-adenosine triphosphatase alpha-subunit. This might contribute to transient hypochlorhydria in patients with H pylori infection
medicine
-
expression of ADAM-17 is significantly increased in gallbladder carcinoma with high histological grade and pT stage compared with low histological grade and pT stage tumors and is not associated with patients gender, age, histological type, and resection margin involvement. Patients with high expression of ADAM-17 have a significantly shorter overall survival compared with those with low expression. The prognostic impact of ADAM-17 is independent of conventional prognostic factors for gallbladder carcinoma
medicine
-
increased expression and shedding of fractalkine by endothelial cells under pro-inflammatory conditions is not regulated by an increased activity of ADAM-17
medicine
-
increased TACE activity is necessary for the release of TNF-alpha observed in anti-Ro/SSA antibodies-stimulated salivary gland epithelial cells
medicine
-
inhibition of ADAM17 increases the cytotoxicity of bortezomib and MDX-060 against L-540 cells
medicine
-
metalloproteases ADAM-9, ADAM-15, and ADAM-17 are upregulated in advanced human atherosclerotic lesions in samples from carotid, aortic, and femoral territories compared to samples from internal thoracic artery free of atherosclerotic plaques. The enzymes are in the catalytically active form. ADAM-9, ADAM-15, and ADAM-17-expressing cells colocalize with CD68-positive cells of monocytic origin in the atherosclerotic plaques. Colocalization is demonstrated in all vascular territories
medicine
-
study on the association of ADAM-17 single nucleotide polymorphisms with insulin-resistance phenotypes and obesity risk. G allele carriers at the ADAM17_m1254A > G polymorphism exhibit significantly higher risk of obesity, are shorter, have higher insulin, and lower HDL-C concentrations than AA subjects. For the ADAM17_i33708A > G single nucleotide polymorphism, homozygotes for the A allele display higher risk of obesity, are heavier, have higher body-mass-index and higher waist measurements than GG subjects. There is a significant gene-diet interaction, in which the deleterious association of the i33708A allele with obesity is observed in subjects with low intakes from n-6 polyunsaturated fatty acids, whereas no differences in obesity risk are seen among subjects with high n-6 polyunsaturated fatty acid intake
medicine
-
transcription factor Sp1 binds to the ADAM17 promoter, and Sp1 regulates ADAM17 expression under hypoxia. Suppression of Sp1 decreases invasiveness and migration in U87 tumor cells
medicine
-
treatment of mice in a lipopolysaccharide-induced endotoxemia model group with recombinant TACE prodomain protein prior to the injection of lipopolysaccharide. The recombinant prodomain protein decreases the release of the secreted TNF-alpha, which mediates the accumulation of TNF-alpha on the surface of macrophage cells. The recombinant protein can decrease the inflammatory response in internal organs of endotoxaemia mice
medicine
-
ADAM17 is a potential drug target in tumor necrosis factor and/or epidermal growth factor receptordependent pathologies in inflammation and cancer
medicine
ADAM17 expression levels are correlated with the invasive ability of androgen-independent prostate cancer cell lines. ADAM17 is overexpressed in cells showing high invasion characteristics, activation of the EGFR-MEK-ERK pathway, up-regulation of MMP-2, MMP-9, and an increased TGF-alpha release into the supernatant. AG1478, PD98059 and antibody against TGF-alpha deactivating the EGFR-MEK-ERK signaling pathway, abolish up-regulation of MMP-2, MMP-9 and prevent cell invasion. Cells with knock-down of ADAM17 by siRNA exhibit low invasive ability, deactivated EGFR-MEK-ERK signaling pathway, reduced TGF-alpha release and down-regulation of MMP-2, MMP-9
medicine
ectopic over-expression of ADAM17 results in increased cell proliferation. ADAM17 promotes G1 to S phase transition concomitantly with upregulation of cyclin E, CDK2 and downregulation of p21 and p27 proteins. ADAM17 over-expression cells show more TGF-alpha released to the supernatant and activate the EGFR/PI3K/AKT pathway. Silencing ADAM17 leads to the opposite effect. Both siRNAs knockdown of ADAM17 and blocking the EGFR/PI3K/AKT pathway cause downregulation of cyclin E,CDK2,and upregulation of p21 and p27 in prostate cancer cells
medicine
human IgG Fc receptor CD16, i.e. FcgammaRIII plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis
medicine
inhibition of ADAM17-mediated processing of TNF-alpha by CD8+ T cells significantly attenuates the diffuse alveolar damage that occurs after T-cell transfer, resulting in enhanced survival. TNF-alpha processing is required for lung epithelial cell expression of CXCL2 and the subsequent inflammatory infiltration. CXCL2 expression is important in acute lung injury
medicine
the enzyme activity plays a positive role to predict cardiovascular events
medicine
the enzyme is upregulated in gastric cancer cells with high metastatic potential
molecular biology
-
results indicate that oxygen regulates the expression of TACE and TACE may be important for placental development during human pregnancy
molecular biology
-
TACE may be involved in liver regeneration by pathway mediated with transforming growth factor-alpha-epidermal growth factor recptor in the cell-cycle progressive phase in vivo. TACE production and effect by paracrine may be a pathway of involvement in liver regeneration for the activated CD3+ T lymphocytes
molecular biology
-
TACE/ADAM17-like proteases might play a role in synaptic formation to generate specific neuronal connections by processing the excess amount of RA175/SynCAM1, a member of the immunoglobulin family 4, located in the non-synaptic region
